Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of Income Statement Information

The following table provides selected income statement information for our single reportable segment (in thousands):

	For the Three Months Ended March 31,
	2025			2024
Net loss before noncontrolling interest	$	(37,952	)	$	(35,333	)
Rental income		230			–
Depreciation and amortization		1,384			832
Equity-based compensation		6,416			7,680
Income tax (benefit) expense		591			98
Interest expense		–			(2	)
Interest income		4,027			4,843

Schedule of Significant Expense Reported to the Chief Operating Decision Maker

The following table provides significant expense categories that are regularly reported to the CODM (in thousands):

	For the Three Months Ended March 31,
	2025			2024
Revenue	$	230		$	–
Clinical trial expense		7,524			8,308
Cash compensation		13,253			10,611
Cash operating expenses		13,143			12,374
Other segment items (1)		4,262			4,040
Net loss before noncontrolling interest	$	(37,952	)	$	(35,333	)

(1)Other segment items primarily include interest income, equity-based compensation and depreciation.